Recently, Freedman et Al [1] brilliantly reviewed the efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.